Submit your Defective Drugs claim details for a free, no obligation case review.
Get Started:
drug_recall bextraAn adverse Bextra reaction can cause serious injury to patients taking this medication. Bextra is a COX-2 selective non-steroidal anti-inflammatory prescription drug manufactured by Pfizer. Bextra was approved by the Food and Drug Administration in November 2001 to treat the severe pain associated with osteoarthritis, rheumatoid arthritis and severe menstrual cramps.
The potential for serious Bextra reaction injuries has become a greater concern since the recall of a similar medication called Vioxx. Vioxx is also a COX-2 selective pain medication that was pulled from the market after clinical trials revealed that taking Vioxx doubled a person''s risk of serious heart problems and stoke. This recall prompted a Bextra reaction, as the cardiovascular safety of all COX-2 selective drugs has come into question. Pfizer and the FDA have indicated plans to test the long term cardiovascular safety of Bextra.
A physically adverse Bextra reaction can occur when a patient experiences the serious side effects associated with taking this pain medication. Symptoms that are common to a negative Bextra reaction can include indigestion, headache, abdominal pain, nausea, and diarrhea.
The most serious Bextra reaction that has been associated with Bextra use is the potential development of serious skin conditions. An adverse Bextra reaction can cause Stevens-Johnson syndrome and toxic epidermal necrolysis. Stevens-Johnson syndrome is characterized by a severe inflammatory eruption of the skin and mucous membranes. Toxic epidermal necrolysis is a condition that causes large portions of the skin to become intensely red and peel off much like a second degree burn would.
These Bextra reaction conditions have been known since the drug was first approved. In 2002 Pfizer was required to include a warning about these serious Bextra reaction skin conditions on all Bextra patient product information. The FDA and Pfizer are currently negotiating the possibility of including a black box warning, the strongest of FDA warnings, on all patient packaging information to warn patients of serious adverse Bextra reaction conditions.
Patients who take Bextra may also be at risk for serious allergic reactions and anaphylactic shock as a result of taking this medication. Signs of any adverse Bextra reaction should be closely monitored in patients who are using this medication. Any adverse Bextra reaction symptoms should be evaluated by a medical professional as soon as they are presented in a patient.
Recent studies presented at the annual American Heart Association conference 2004, suggested a possible link between adverse cardiovascular symptoms and a Bextra reaction. Patients who are taking Bextra should be closely monitored for any signs of heart problems or stoke as it is still unclear if taking Bextra poses additional cardiovascular and stroke risks.
Bextra , the popular cox-2 inhibitor recalled by Pfizer, is the subject of another lawsuit.
Rita Fohne has filed her lawsuit against Pfizer in Madison County, Illinois, seeking ...
The U.S. Food and Drug Administration has started issuing alerts to patients and doctors on its new site Drug Watch. Including emerging drug-safety concerns, as well as dangers presented by drugs prescribed for unapproved uses, the new site is in resp...
After a controversial year of drug recalls, the FDA was under attack for failing to adequately protect consumers from dangerous drugs. Currently, the FDA has the Adverse Event Reporting System, or AERS, to collect voluntary reports of possible reactio...